Target detail
RELA
RELA proto-oncogene, NF-kB subunit
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: RELA proto-oncogene, NF-kB subunit
Aliases: RELA, RELA proto-oncogene, NF-kB subunit
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000173039
Index freshness: last_synced_at 2026-05-15T17:46:27.598+00:00 · updated 2026-05-15T17:46:27.984785+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for RELA. Empty groups mean no matching rows — not a claim about biology or clinical use.
- ClinicalTrials.govLive when indexed
Registry mirror rows in clinical_trials when operators run the CT.gov enrichment CLI — browser never calls the registry directly.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
Rows from disease_target_evidence for this symbol.
glioblastoma
literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
No linked drug rows
When drug_targets and drugs rows exist for this symbol, they are listed here.
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
NCT00782756 — Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00979862 — Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00387933 — Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02179086 — Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov
Open trials hubNCT02661282 — Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02311920 — Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02800486 — Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT05956821 — Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT05708352 — A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT02664363 — EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT02658981 — Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT04846257 — Specific Preoperative Dynamic Contrast-enhanced MRI Semi-quantitative Markers Can Correlate With Vascularity in Specific Areas of the Glioblastoma Tissue and Predict Recurrence
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00884741 — Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02444546 — Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00095940 — Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00499473 — Sunitinib in Treating Patients With Recurrent Malignant Gliomas
Status: COMPLETED · clinicaltrials.gov
Open trials hubRepurposing signal rows for drugs linked to this target via drug_targets.
No research signals for linked drugs
Run the deterministic signal builder after drug_targets and source rows are present.
Structured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
- clinicaltrials.gov: 16
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
No matching live evidence found
When repurposing_signal rows reference this marker via linked drugs, summaries appear here.